Gmax Biopharm LLC
π¨π³China
- Country
- π¨π³China
- Ownership
- Holding, Subsidiary
- Established
- 2010-09-02
- Employees
- 153
- Market Cap
- -
- Website
- https://www.gmaxbiopharm.com
A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension
Phase 1
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Q4W GMA301 IV injections (1800 mg)Drug: Q4W GMA301 IV injections (300 mg)Drug: Q4W GMA301 IV injections (600 mg)Drug: Q4W GMA301 IV injections (1000 mg)Other: Q4W placebo IV injections
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Gmax Biopharm LLC.
- Target Recruit Count
- 48
- Registration Number
- NCT04503733
- Locations
- π¨π³
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
π¨π³Shanghai Pulmonary Hospital, Shanghai, China
π¨π³Guangdong General Hospital, Guangzhou, China
Β© Copyright 2025. All Rights Reserved by MedPath